Összesen 89 elem 9 oldalon, 10 listázva, a(z) 1. oldal megjelenítve.Következő oldalÁtlépés a keresőbeIn English
Megjegyzés: Funding Agency and Grant Number: Hungarian National Research, Development, and Innovation Office [K 139330, PD 146014, PD 134449]; Hungarian Brain Research Program 3.0 [NAP2022-I-4/2022]; Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund [TKP2021-EGA-25, TKP2021-EGA-02]; European Union [RRF-2.3.1-21-2022-00004]; Janos Bolyai Research Scholarship of the Hungarian Academy of Sciences; Academy of Finland [ERAPERMED2019-108]; Catalan Department of Health [ERAPERMED2019-108, SLD002/19/000002]; [2019-2.1.7-ERA-NET-2020-00005]; [OTKA K 143391]; [EKOP-2024-68]
Funding text: This study was supported by the Hungarian National Research, Development, and Innovation Office 2019-2.1.7-ERA-NET-2020-00005 under the frame of ERA PerMed (ERAPERMED2019-108) ; by the Hungarian National Research, Development, and Innovation Office OTKA K 143391, K 139330, PD 146014, and PD 134449 grants; by the Hungarian Brain Research Program 3.0 (NAP2022-I-4/2022) ; and by TKP2021-EGA-25 and TKP2021-EGA-02, supported by the Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund, under the TKP2021-EGA funding scheme; and the European Union project [RRF-2.3.1-21-2022-00004] within the framework of the Artificial Intelligence National Laboratory. Dora Torok is supported by EKOP-2024-68. Nora Eszlari is supported by the Janos Bolyai Research Scholarship of the Hungarian Academy of Sciences. The study was funded by the Academy of Finland under the frame of ERA PerMed (TRAJECTOME project, ERAPERMED2019-108) . The Catalan cohort was extracted from the Catalan Health Surveillance System database, owned and managed by the Catalan Health Service, with the earnest collaboration of the Digitalization for the Sustainability of the Healthcare (DS3) -IDIBELL group. The study was supported by the Catalan Department of Health (SLD002/19/000002) under the frame of ERA PerMed (ERAPERMED2019-108) .Megjegyzés: Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, 17475, Germany
Department of Pharmacodynamics, Faculty of Pharmaceutical Sciences, Semmelweis University, Nagyvárad tér 4., Budapest, H-1089, Hungary
NAP3.0-SE Neuropsychopharmacology Research Group, Hungarian Brain Research Program, Semmelweis University, Üllői út 26., Budapest, H-1085, Hungary
Department of Measurement and Information Systems, Budapest University of Technology and Economics, Műegyetem rkp. 3., Budapest, H-1111, Hungary
Department of Public Health and Welfare, Finnish Health and Welfare Institute. Biomedicum 1, Haartmaninkatu 8, Helsinki, 00290, Finland
Department of Human Genetics and South Texas Diabetes and Obesity Institute, School of Medicine at University of Texas Rio Grande Valley, Brownsville, TX, United States
Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Finland
Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Villarroel 170, Barcelona, 08036, Spain
German Centre for Neurodegenerative Diseases (DZNE), Site Rostock/Greifswald, Greifswald, 17475, Germany
Export Date: 25 July 2024
CODEN: JADID
Correspondence Address: Van der Auwera, S.; Department of Psychiatry and Psychotherapy, Germany; email: Sandra.auwera@uni-greifswald.deMegjegyzés: Funding Agency and Grant Number: National Research, Development and Innovation Office of Hungary (NKFIH) OTKA Grant [PD 134449, OTKA K 139330]; European Union (EU) Joint Program on Neurodegenerative Disease (JPND) Grant SOLID [JPND2021-650-233]; National Research, Development, and Innovation Fund of Hungary [TKP2021-EGA-02]; European Union project within the framework of the Artificial Intelligence National Laboratory [RRF-2.3.1-21-2022-00004]
Funding text: This work was supported by the National Research, Development and Innovation Office of Hungary (NKFIH) OTKA Grant [PD 134449 to A.G., OTKA K 139330 to P.A.], the European Union (EU) Joint Program on Neurodegenerative Disease (JPND) Grant SOLID [JPND2021-650-233], the National Research, Development, and Innovation Fund of Hungary [Grant TKP2021-EGA-02], and the European Union project [RRF-2.3.1-21-2022-00004] within the framework of the Artificial Intelligence National Laboratory.Megjegyzés: Department of Artificial Intelligence and Systems Engineering, Budapest University of Technology and Economics, Budapest, Hungary
Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany
German Centre for Neurodegenerative Diseases (DZNE), Site Rostock/Greifswald, Greifswald, Germany
Department of Public Health and Welfare, Population Health Unit, Public Health Research Team, Finnish Institute for Health and Welfare, Helsinki, Finland
Department of Pharmacodynamics, Faculty of Pharmaceutical Sciences, Semmelweis University, Budapest, Hungary
NAP3.0-SE Neuropsychopharmacology Research Group, Hungarian Brain Research Program, Semmelweis University, Budapest, Hungary
Clínic Barcelona, Fundació de Recerca Clinic Barcelona - Institut d’Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Universitat de Barcelona, Barcelona, Spain
Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary
Abiomics Europe Ltd., Budapest, Hungary
Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany
Department of Human Genetics and South Texas Diabetes and Obesity Institute, School of Medicine at University of Texas Rio Grande Valley, Brownsville, TX, United States
Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland
Export Date: 3 September 2024
Correspondence Address: Juhasz, G.; Department of Pharmacodynamics, Hungary; email: juhasz.gabriella@semmelweis.huMegjegyzés: Funding Agency and Grant Number: European Research Area on Personalized Medicine (ERA PerMed) program [ERAPERMED2019-108]; Academy of Finland; Hungarian National Research, Development, and Innovation Office [2019-2.1.7-ERA-NET-2020-00005K143391, K139330, PD 134449]; Hungarian Brain Research Program 3.0 [NAP2022-I-4/2022]; Ministry for Innovation and Technology of Hungary from the National Research, Development, and Innovation Fund under the TKP2021-EGA [TKP2021-EGA-25, TKP2021-EGA-02]; European Union [RRF-2.3.1-21-2022-00004]
Funding text: This initiative was supported by European Research Area on Personalized Medicine (ERA PerMed) program ("Temporal disease map based stratification of depression-related multimorbidities: towards quantitative investigations of patient trajectories and predictions of multi-target drug candidates" [TRAJECTOME] project; ERAPERMED2019-108) . Locally, this study was supported by the Academy of Finland under the frame of the ERA PerMed program and the Hungarian National Research, Development, and Innovation Office (2019-2.1.7-ERA-NET-2020-00005K143391, K139330 and PD 134449 grants) ; the Hungarian Brain Research Program 3.0 (NAP2022-I-4/2022) ; and the Ministry for Innovation and Technology of Hungary from the National Research, Development, and Innovation Fund under the TKP2021-EGA funding scheme (TKP2021-EGA-25 and TKP2021-EGA-02) . This study was supported by the European Union project RRF-2.3.1-21-2022-00004 within the framework of the Artificial Intelligence National Laboratory. The authors want to acknowledge the earnest collaboration of the Digitalization for the Sustainability of the Healthcare System research group at Institut d'Investigacio Biomedica de Bellvitge (IDIBELL) for their support in the preparation of the Catalan cohort, which was extracted from the Catalan Health Surveillance System database, owned and managed by the Catalan Health Service. In addition, the authors want to acknowledge the participants and investigators of the FinnGen study and CSC-IT Center for Science, Finland, for computational resources. This research was conducted using the UK Biobank resource under application 1602. Linked health data Copyright 2019, NHS England. Reused with the permission of the UK Biobank. All rights reserved.Megjegyzés: Acknowledgements: The TRAJECTOME project (https://semmelweis.hu/TRAJECTOME/TRAJECTOME/) was supported by the ERA PerMed Joint Translational Call 2019 (application number: ERAPERMED2019-108). At national level the project was funded by the National Research, Development and Innovation Offi ce (2019-2.1.7-ERA-NET-2020-00005), Hungary; by the Federal Ministry of Education and Research (BMBF, gr. No. 01KU2004), Germany; by the Academy of Finland under the frame of ERA PerMed (TRAJECTOME project, ERAPERMED2019-108), Finland; and by the Catalan Department of Health (SLD002/19/000002), Spain. The UK Biobank database resource was utilised under application number 1602, which includes medical and phenotypic data of recruited participants on the NHS patient registers of people aged 40–69 years [51].
Megjegyzés: Dept. of Paediatrics, Semmelweis University, Budapest, Hungary
Dept. of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest, Hungary
Dept. of Measurement and Information Systems, Budapest University of Technology and Economics, Budapest, Hungary
Institute of Genomic Medicine and Rare Disorders, Semmelweis University, Budapest, Hungary
HCEMM-SE Molecular Oncohematology Research Group, 1st Dept. of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary
Dept. of Anatomy, Cell and Developmental Biology, ELTE Eötvös Loránd University, Budapest, Hungary
Dept. of Plant Physiology and Molecular Plant Biology, ELTE Eötvös Loránd University, Budapest, Hungary
Heim Pál Children Hospital, Budapest, Hungary
Cited By :1
Export Date: 24 April 2023
CODEN: MCPRE
Correspondence Address: Semsei, Á.F.; Dept. of Genetics, 1085 Üllői út 26, Hungary; email: semsei.agnes@med.semmelweis-univ.hu